ReviewNeuroradiology2026
The neuroimaging spectrum of subacute sclerosing panencephalitis: a systematic review.
Review in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe conducted a comprehensive analysis of spectrum of neuroimaging findings in Subacute Sclerosing Panencephalitis (SSPE) across case reports and cohort studies.
methodsA systematic review was conducted as per PRISMA guidelines. Electronic databases were searched from inception using predefined terms related to SSPE and neuroimaging. Eligible studies included confirmed cases with reported imaging findings from case reports, case series, and cohort studies.
resultsAmong 461 reported cases, neuroimaging was performed in 456 (98.9%), with MRI in 394 (85.5%) and CT in 58 (12.6%). White-matter abnormalities were identified in 431 (93.5%), most commonly diffuse bilateral (132, 28.6%), periventricular (104, 22.6%), subcortical (71, 15.4%), and posterior parieto-occipital-predominant patterns (63, 13.7%). Cortical involvement was present in 247 (53.6%), including diffuse hemispheric changes (74, 16.1%) and posterior predominance (68, 14.8%). Deep gray matter lesions occurred in 79 (17.2%), involving basal ganglia (47, 10.2%) and thalamus (23, 5.0%), while brainstem abnormalities were observed in 34 (7.4%). Diffusion restriction was reported in 52 (11.3%), contrast enhancement in 38 (8.2%), and cerebral atrophy in 162 (35.1%), including progressive atrophy in 63 (13.7%). Imaging mimics included ocular-first/visual pathway-predominant patterns (46, 10.0%), autoimmune encephalitis/ADEM-like patterns (37, 8.0%), leukodystrophy-like changes (31, 6.7%), stroke-like presentations (29, 6.3%), and basal ganglia-predominant forms (26, 5.6%).
conclusionsNeuroimaging in SSPE shows predominant bilateral white matter involvement with posterior distribution, variable cortical and deep gray extension, progressive atrophy, limited enhancement, and frequent radiological mimics, reflecting a stage-evolving heterogeneous process.
Indexed as
Identifiers
42113281What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.